利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.023 秒)

    Blood coagulation protein antagonists and uses therefor
    4.
    发明授权
    Blood coagulation protein antagonists and uses therefor 失效
    凝血蛋白拮抗剂及其用途

    公开(公告)号：US5843442A

    公开(公告)日：1998-12-01

    申请号：US453047

    申请日：1995-05-30

    申请人： Howard R. Soule ,  Terence K. Brunck

    发明人： Howard R. Soule ,  Terence K. Brunck

    IPC分类号： A61K38/00 ,  C07K16/40 ,  A61K39/395 ,  C07K16/00 ,  C07K16/18

    CPC分类号： C07K16/40 ,  A61K38/00

    摘要： Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.

    摘要翻译： 公开了凝血蛋白拮抗剂，其包括公开用于产生针对因子VII和VIIa的特异性中和抗体和组织因子/因子VIIa双分子复合物的单克隆抗体和相关细胞系，所述抗体可用于预防或治疗 血栓形成和相关疾病，用于免疫亲和分离和纯化因子VII和VIIa和组织因子/因子VIIa复合物，以及用于测定生物样品中因子VII或VIIa和组织因子/因子VII或VIIa复合物。

    HTLV-I anti-sense RNA and encoded proteins
    5.
    发明授权
    HTLV-I anti-sense RNA and encoded proteins 失效
    HTLV-I反义RNA和编码蛋白

    公开(公告)号：US4999421A

    公开(公告)日：1991-03-12

    申请号：US211749

    申请日：1988-06-27

    申请人： Terence K. Brunck ,  David J. Larocca ,  John J. Monahan

    发明人： Terence K. Brunck ,  David J. Larocca ,  John J. Monahan

    IPC分类号： A61K39/00 ,  C07K14/15

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2740/14022 ,  Y10S530/806

    摘要： The mRNA coded by the "anti-sense" strand of the complementary DNA produced by HTLV-I infection contains significant open reading frames. Cells infected by HTLV-I virus produce mRNA that is anti-sense to the viral RNA genome. Infected cells may produce proteins from the newly discovered mRNA. The production of the anti-sense in mRNA initiates from a newly discovered transcriptional promoter located within 1.8 kb from the 3' terminus of the viral genome. The mRNA, protein, and antibodies directed thereto can be used in the prevention, diagnosis, and treatment of HTLV-I infections.

    摘要翻译： 由HTLV-I感染产生的互补DNA的“反义”链编码的mRNA含有显着的开放阅读框架。 感染HTLV-I病毒的细胞产生对病毒RNA基因组无害的mRNA。 受感染的细胞可能从新发现的mRNA产生蛋白质。 mRNA中反义词的产生从位于距病毒基因组3'末端1.8kb的新发现的转录启动子起始。 指向其的mRNA，蛋白质和抗体可用于预防，诊断和治疗HTLV-1感染。

    Inhibitors of urokinase and blood vessel formation
    6.
    发明授权
    Inhibitors of urokinase and blood vessel formation 失效
    抑制尿激酶和血管形成

    公开(公告)号：US06432922B1

    公开(公告)日：2002-08-13

    申请号：US09359929

    申请日：1999-07-22

    申请人： Terence K. Brunck ,  Susan Y. Tamura

    发明人： Terence K. Brunck ,  Susan Y. Tamura

    IPC分类号： C07K506

    CPC分类号： C07K5/06069 ,  A61K38/00

    摘要： Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

    摘要翻译： 提供了具有尿激酶活性抑制剂和减少或抑制血管形成的新型化合物。 这些化合物在P1处具有精氨酸或精氨酸模拟醛或精氨酸酮酰胺基团。 这些化合物在体外可用于监测纤溶酶原激活物水平和体内治疗通过抑制或降低尿激酶活性和改善血管形成与病理状况相关的病理状况而改善的病症。

    Blood coagulation protein antagonists and uses therefor
    7.
    发明授权
    Blood coagulation protein antagonists and uses therefor 失效
    凝血蛋白拮抗剂及其用途

    公开(公告)号：US06221659B1

    公开(公告)日：2001-04-24

    申请号：US09008121

    申请日：1998-01-16

    申请人： Howard R. Soule ,  Terence K. Brunck

    发明人： Howard R. Soule ,  Terence K. Brunck

    IPC分类号： C12N506

    CPC分类号： C07K16/40 ,  A61K38/00

    摘要： Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.

    摘要翻译： 公开了凝血蛋白拮抗剂，其包括公开用于产生针对因子VII和VIIa的特异性中和抗体和组织因子/因子VIIa双分子复合物的单克隆抗体和相关细胞系，所述抗体可用于预防或治疗 血栓形成和相关疾病，用于免疫亲和分离和纯化因子VII和VIIa和组织因子/因子VIIa复合物，以及用于测定生物样品中因子VII或VIIa和组织因子/因子VII或VIIa复合物。